Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 131
3 149
2 51
1 25
NEB 4
Curative setting
A 53
C 2
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 37
Endocrine Tumours 21
Gastrointestinal Cancers 69
Genitourinary Cancers 70
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 1
Sarcoma 11
Skin Cancers 29
Thoracic Malignancies 83
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 16
Genitourinary Cancers 3
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 2
Skin Cancers 14
Thoracic Malignancies 10
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Erlotinib - Carboplatin gemcitabine Locally advanced or metastatic NSCLC with EGFR activating mutations OPTIMAL, CTONG-0802
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ OPTIMAL, CTONG-0802

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Erlotinib - Platinum-based chemotherapy doublet Locally advanced or metastatic NSCLC with EGFR activating mutations EURTAC
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ EURTAC

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Gefitinib - Carboplatin + paclitaxel Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase. IPASS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ IPASS

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Afatinib - Cisplatin + pemetrexed As monotherapy for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s) LUX - Lung 3
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ LUX - Lung 3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Afatinib - Cisplatin + pemetrexed As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) - Del19/L858R pre-planned subgroup analysis LUX - Lung 3
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ LUX - Lung 3

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Osimertinib - Platinum/pemetrexed Osimertinib used as monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. AURA3
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ (T790M ) AURA3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Crizotinib - Chemotherapy Treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) PROFILE 1007
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ PROFILE 1007

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Crizotinib - Pemetrexed + cisplatin or carboplatin First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) PROFILE 1014
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ PROFILE 1014

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Pemetrexed - Placebo As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - -

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Pemetrexed Cisplatin Cisplatin + gemcitabine In combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - -

    4

    PRELIMINARY SCORE

    • NI

    ADJUSTMENTS

    SCORE

    • F2c
      4
    Palliative care Chemotherapy Chemotherapy First-line treatment stage IV NSCLC ECOG<2
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - -

    4

    PRELIMINARY SCORE

    • NI

    ADJUSTMENTS

    SCORE

    • F2c
      4
    Pembrolizumab - Platinum-based chemotherapy First line treatment of mNSCLC with tumour PD-L1 expression ≥50% TPS with no EGFR or ALK positive tumour mutations KEYNOTE-24
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥50% KEYNOTE-24

    A

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      5

      A
    Bevacizumab Erlotinib Erlotinib In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations JO25567
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ JO25567

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Afatinib - Erlotinib As monotherapy for the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based ChT LUX - Lung 8
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - Squamous cell - LUX - Lung 8

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Bevacizumab Paclitaxel + carboplatin Paclitaxel + carboplatin First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - -

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Ramucirumab Docetaxel Docetaxel + placebo In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic NSCLC with disease progression after platinum-based chemotherapy REVEL
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - REVEL

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Necitumumab Gemcitabine + cisplatin Gemcitabine + cisplatin Locally advanced or metastatic EGFR-expressing squamous NSCLC without prior ChT SQUIRE
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - Squamous cell - SQUIRE

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Erlotinib - Placebo Locally advanced or metastatic NSCLC with EGFR-activating mutations and stable disease after first-line ChT SATURN
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ SATURN

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Imiquimod 5% cream - Placebo For the topical treatment of small superficial basal cell carcinomas (cBCCs) in adults
    Skin Cancers
    		 Basal Cell Carcinoma - -

    C

    PRELIMINARY SCORE

    • pCR

    ADJUSTMENTS

    SCORE

    • F1

      C
    Ipilimumab - Placebo Patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm who have undergone complete resection, including total lymphadenectomy EORTC 18071
    Skin Cancers
    		 Cutaneous Melanoma - EORTC 18071

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Nivolumab + Ipilimumab - Ipilimumab Ipilimumab in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older* CheckMate 067
    Skin Cancers
    		 Cutaneous Melanoma - CheckMate 067

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Nivolumab - Ipilimumab Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older* CheckMate 067
    Skin Cancers
    		 Cutaneous Melanoma - CheckMate 067

    A

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      4

      A
    Ipilimumab - Glycoprotein 100 (GP100) Second-line treatment in advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (pre-immunotherapy era) MDX010-20
    Skin Cancers
    		 Cutaneous Melanoma HLA-A*0201 MDX010-20

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Vemurafenib - Dacarbazine As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma BRIM-3
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600E BRIM-3

    4

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      4
    Vemurafenib - Dacarbazine As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma BRIM-3
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600K BRIM-3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Trametinib - Dacarbazine or paclitaxel As monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation METRIC
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 METRIC

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Dabrafenib + trametinib - Dabrafenib Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation COMBI-d
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 COMBI-d

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Dabrafenib - Dacarbazine Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation BREAK-3
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600E BREAK-3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Dab/Tram (dabrafenib and trametinib) - Vemurafenib Dabrafenib in combination with trametinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation COMBI-v
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600 COMBI-v

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Cobimetinib Vemurafenib Vemurafenib + placebo In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation coBRIM
    Skin Cancers
    		 Cutaneous Melanoma BRAF V600E coBRIM

    A

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      5

      A

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.